PhosphoSolutions is excited to announce Immunochemistry Technologies (ICT) has joined our growing family that also includes Antibodies Incorporated, and Aves Labs.
We sat down with 2019 HHMI Hanna H. Gray Fellow Christopher Bartley, MD/PhD to discuss the background of Fragile X Mental Retardation Protein (FMRP) and how PhosphoSolutions’ anti-phospho-Ser499 FMRP antibody played a crucial role in helping further his research.
Every year CiteAb celebrates the very best suppliers and individuals in the research reagent sector worldwide. For 2020, PhosphoSolutions’ very own Mike Browning was selected to receive a Lifetime Achievement Award. His illustrious career in academia and the bioscience sector has spanned four decades. He has helped shape the antibody industry as a neuroscientist, mentor, and business leader.
PhosphoSolutions is proud to announce its new partnership with Aves Labs and Antibodies Incorporated!
With the addition of Antibodies Incorporated and Aves Labs, the combined team will be able to provide researchers with a broader range of tools produced in multiple species to advance neuroscience studies. As researchers continue to push boundaries, the team will be able to offer a toolkit to match, with highly-validated reagents that also open up new possibilities for multiplex labeling.
10 February 2017.
Authors: Kameron Simpson, Michael Browning
PhosphoSolutions addresses the reproducibility crisis by discussing some of the biggest contributing factors to the “antibody problem”, including steps that can be taken on both the production side as well as on the side of the end-user. We go in-depth to discuss the initial screening via Western Blot that should be done by researchers to confirm antibody quality. We then describe steps that should be taken by producers of polyclonal antibodies to ensure lot-to-lot consistency.
Letter to the Editor of Nature Methods from founder Mike Browning:
Should we ignore Western blots when selecting antibodies for other applications?
28 February 2017
An antibody may behave differently in different applications, and it is important to validate the antibody in an application-specific manner. However, Western blotting plays a vital role in establishing the potential for cross reactivity of an antibody, and should not be excluded from the validation process even if the final goal is for the
antibody to be used in IHC or IF.
18 November 2015
Independent researchers writing for PLoS compared our FMRP phospho-antibody to another commercially available FMRP antibody. The results were clear: The PhosphoSolutions antibody had greater specificity and less variability.
15 September 2015. Author: Michael D. Browning
The scientific community is putting an increasing focus on antibody inconsistency. We believe that these issues can be overcome by addressing two of the biggest offenders: antibody validation and antibody variability. Antibody suppliers must address the variability problem so that scientists can provide validation.
We call this the Antibody Two-Step Solution.
30 July 2013
Antibody based assays are a crucial part of research labs around the world. A variety of factors such as the variability inherent in biology, differences in applications, and the structure of the antibody marketplace make the quest for quality antibodies a difficult one. Our founder was interviewed to address these issues and provide tips for
researchers who are looking for antibodies that work.
24 January 2011.
Authors: Amy J. Archuleta, Crystal A. Stutzke, Kristin M. Nixon, Michael D. Browning
PhosphoSolutions goes in-depth to discuss the essential protocols and methods necessary to create a phospho-specific antibody that works. We describe techniques used from the beginning to the end of the antibody development process. We start with antigen design and immunization, continue with antibody purification, and even discuss the best ways to characterize the phosphospecificity of the antibody in peptide ELISA and western blots.